---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-009350"
form_type: "8-K"
ticker: "TNYA"
cik: "0001858848"
company_name: "Tenaya Therapeutics, Inc."
filed_at: "2022-05-11T23:59:59+00:00"
generated_at: "2026-06-25T21:13:22.045076+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Tenaya Q1 net loss $31.1M; TN-201 gets EU orphan designation, IND filings on track

## Summary
- Cash, equivalents and marketable securities of $213.5M at March 31; runway into H2 2023.
- Net loss of $31.1M ($0.75/sh) for Q1 2022; R&D expense $24.2M, G&A $7.0M.
- TN-201 received EU Orphan Medicinal Product designation for MYBPC3 HCM; IND expected H2 2022.
- Preclinical TN-401 data at Heart Rhythm 2022 showed restored heart function, reduced arrhythmia, increased survival; IND expected 2023.
- cGMP manufacturing facility in Union City expected operational H1 2022.

## SEC filing metadata
- accession: 0000950170-22-009350
- form_type: 8-K
- ticker: TNYA
- cik: 0001858848
- company_name: Tenaya Therapeutics, Inc.
- filed_at: 2022-05-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1858848/000095017022009350/0000950170-22-009350-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1858848/000095017022009350/tnya-20220511.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-009350
- JSON: https://secwatch.observer/filing/0000950170-22-009350.json
- Plain text: https://secwatch.observer/filing/0000950170-22-009350.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.